GenericRadar
Market LIVE
Published markets; coverage varies by country
Product profile · United States

AVYCAZ

 ·  Patent Litigation & Settlement History ↓

IngredientAVIBACTAM SODIUM; CEFTAZIDIME
Application typeNDA
Application206494
Product001
Dosage formPOWDER
RouteINTRAVENOUS
StrengthEQ 0.5GM BASE;2GM/VIAL
Approval date2015-02-25
Marketing statusPrescription
Status event—
ApplicantABBVIE
Product source

Current GenericRadar decision

Year2026
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeDS_EQUIVALENT_PATENT
Anchor date2026-11-12
Patent anchor2026-11-12
Exclusivity anchor2025-02-25
Protection date2032-06-15
First Final ANDA—
Status event—

POST_ANCHOR_RIGHTS_EXIST; US:NDA:206494:001; exact Final ANDA not verified; not proof of generic absence

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
71125922026-01-07DS/DP/U U-282YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
71125922026-01-07DS/DP/U U-3818YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
71125922026-01-07DS/DP/U U-2244YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
71125922026-01-07DS/DP/U U-2508YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
71125922026-01-07ORANGE_BOOK U-2244;U-2508;U-282;U-3818YNTRUE_DS
English description not available.
———
76120872026-11-12DP —NYU
| B1C03P7 issued-claim review2026-10-15: U
———
76120872026-11-12ORANGE_BOOK —NYU
English description not available.
———
88354552030-10-08DP —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
88354552030-10-08ORANGE_BOOK —NNDP
English description not available.
———
84710252031-08-12DS —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
84710252031-08-12ORANGE_BOOK —NNDP
English description not available.
———
89695662032-06-15DS —NNOTHER
| B1C03P7 issued-claim review2026-10-15: OTHER
———
89695662032-06-15ORANGE_BOOK —NNOTHER
English description not available.
———
92843142032-06-15DS —NNOTHER
| B1C03P7 issued-claim review2026-10-15: OTHER
———
92843142032-06-15ORANGE_BOOK —NNOTHER
English description not available.
———
96951222032-06-15DS —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
96951222032-06-15ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2015-02-252020-02-25English description not available.YY2020-02-25
GAIN
Full coverage date: 2020-02-25
Source
GAIN2015-02-252025-02-25English description not available.YY2025-02-25
GAIN
Full coverage date: 2025-02-25
Source
NPP2022-12-202025-12-20English description not available.NN—
GAIN
Full coverage date: —
Source
NPP2024-01-262027-01-26English description not available.NN——Source
NPP2024-01-262027-01-26English description not available.NN—
GAIN
Full coverage date: —
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (12)
TypeDateRoleBasisSource
PATENT2026-01-07HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2026-11-12CANONICAL_ANCHOREnglish description not available.Source
PATENT2030-10-08FTO_TAILEnglish description not available.Source
PATENT2031-08-12FTO_TAILEnglish description not available.Source
PATENT2032-06-15FTO_TAILEnglish description not available.Source
PATENT2032-06-15FTO_TAILEnglish description not available.Source
PATENT2032-06-15FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—FTO_TAILEnglish description not available.Source
REGULATORY_STATUS2026-11-12CANONICAL_DECISIONPOST_ANCHOR_RIGHTS_EXIST; US:NDA:206494:001; exact Final ANDA not verified; not proof of generic absenceSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.